Trial Profile
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Collagenase clostridium histolyticum (Primary)
- Indications Peyronie's disease
- Focus Registrational; Therapeutic Use
- Acronyms IMPRESS
- Sponsors Auxilium Pharmaceuticals
- 04 Sep 2020 Results of post hoc analysis from NCT02298829, NCT01221597, NCT01221623, NCT01243411 and NCT01685437 determoning the long-term (5 year) efficacy and safety profile of CCH in men subgrouped by the degree of penile plaque calcification prior to treatment, published in the Urology
- 19 May 2015 Results presented at the American Urological Association (AUA) at its 110th Annual Scientific Meeting, as reported by Endo Pharmaceuticals media release.
- 30 Jan 2015 According to a Swedish Orphan Biovitrum AB media release, the EU Commission has approved Xiapex for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.